Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.
PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.
研究概览
详细说明
OBJECTIVES:
- Compare the effect of adjuvant therapy with pegylated interferon alfa vs observation, in terms of distant metastases-free survival, in patients with previously resected stage III melanoma.
- Compare the overall survival in these patients after treatment with pegylated interferon alfa vs observation.
- Determine the toxicity of pegylated interferon alfa in these patients.
- Determine the compliance of these patients treated with pegylated interferon alfa.
- Compare the quality of life in these patients after treatment with pegylated interferon alfa vs observation.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to type of nodal involvement (N1 vs N2), number of positive nodes (1 vs 2-4 vs 5 or more vs not assessed), Breslow primary (T1-2 vs T3 vs T4 vs unknown), ulceration of primary tumor (absent vs present vs unknown), sex, and center. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive pegylated interferon alfa subcutaneously weekly for 5 years.
- Arm II: Patients undergo observation only. Treatment continues in the absence of distant metastases or unacceptable toxicity.
Quality of life is assessed at baseline, and then at months 3, 12, 24, 36, 48, and 60.
Patients are followed every 6 months for 5 years.
PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this study within 1.5-2 years.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Haifa、以色列、31096
- Rambam Medical Center
-
Holon、以色列、58100
- Wolfson Medical Center
-
Tel-Aviv、以色列、64239
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Sofia、保加利亚、1756
- National Centre of Oncology
-
-
-
-
-
Zagreb、克罗地亚、10000
- University Hospital Sestre Milosrdnice
-
-
-
-
-
Berlin、德国、D-13122
- Robert Roessle Klinik
-
Bochum 1、德国、D-44791
- Saint Josef Hospital
-
Dortmund、德国、44123
- Stadt. Kliniken
-
Erlangen、德国、D-91054
- Universitaet Erlangen
-
Goettingen、德国、D-37075
- Georg August Universitaet
-
Hamburg、德国、D-22765
- Haematologisch-Onkologische Praxis Altona
-
Heidelberg、德国、D-69115
- Universitaets-Hautklinik Heidelberg
-
Leipzig、德国、D-04103
- Universitaet Leipzig - Chirurgische Klinik und Poliklinik I
-
Magdeburg、德国、D-39120
- Otto - Von - Guericke - Universitaet Magdeburg
-
Mannheim、德国、D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg、德国、D-97080
- Universitaet Wuerzburg/Hautkrankheiten
-
-
-
-
-
Aviano、意大利、33081
- Centro di Riferimento Oncologico - Aviano
-
Firenze、意大利、I-50011
- Ospendale S.M. Annunziata-A.S.DI Firenze
-
Genoa (Genova)、意大利、16132
- Istituto Nazionale per la Ricerca sul Cancro
-
Milano、意大利、20141
- European Institute of Oncology - Chemo Prevention
-
Milano (Milan)、意大利、20133
- Istituto Nazionale per lo Studio e la Cura dei Tumori
-
Naples、意大利、80131
- Istituto Nazionale per lo Studio e la Cura dei Tumori
-
Rome、意大利、00161
- Istituto Regina Elena
-
Torino、意大利、10126
- Universita Degli Studi di Torino
-
-
-
-
-
Prague (Praha)、捷克共和国、128 08
- Charles University Hospital
-
-
-
-
-
Ljubljana、斯洛文尼亚、Sl-1000
- Institute of Oncology, Ljubljana
-
-
-
-
-
Brussels、比利时、1200
- Cliniques universitaires Saint-Luc
-
Brussels、比利时、1000
- Institut Jules Bordet
-
Brussels、比利时、1070
- Hopital Universitaire Erasme
-
Edegem、比利时、B-2650
- Universitair Ziekenhuis Antwerpen
-
Gosselies、比利时、6041
- Clinique Notre Dame de Grâce
-
Leuven、比利时、B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Amiens、法国、80054
- Centre Hospitalier Universitare d'Amens
-
Besancon、法国、25030
- CHR de Besancon - Hopital Saint-Jacques
-
Bordeaux、法国、33075
- Hopital Saint André
-
Boulogne Billancourt、法国、F-92104
- CHU Ambroise Paré
-
Grenoble、法国、38043
- Chr De Grenoble - La Tronche
-
Lille、法国、59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Limoges、法国、87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon、法国、69373
- Centre Léon Bérard
-
Montpellier、法国、34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Montpellier、法国、34295
- Hopital St. Eloi
-
Nice、法国、F-06202
- Hopital L'Archet - 2
-
Paris、法国、75018
- Hopital Bichat - Claude Bernard
-
Paris、法国、75475
- Hôpital Saint-Louis
-
Pessac、法国、33604
- Hopital Haut Lévêque
-
Reims、法国、51092
- Centre Hospitalier Universitaire
-
Rennes、法国、35042
- Centre Eugene Marquis
-
Saint Cloud、法国、92211
- Centre René Huguenin
-
Saint Priest en Jarez、法国、42277
- Centre Hospitalier Regional et Universitaire de Saint-Etienne
-
Strasbourg、法国、67091
- Hopitaux Universitaire de Strasbourg
-
Thionville、法国、57126
- Centre Hospitalier Régional Metz Thionville
-
Tours、法国、37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
Vandoeuvre-les-Nancy、法国、54511
- Centre Alexis Vautrin
-
Villejuif、法国、F-94805
- Institut Gustave Roussy
-
-
-
-
-
Poznan、波兰、61 866
- Great Poland Cancer Center
-
Warsaw、波兰、02-781
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
-
-
-
-
-
Newcastle、澳大利亚、NSW 2300
- David Maddison Clincial Sciences
-
-
Victoria
-
East Melbourne、Victoria、澳大利亚、8006
- Peter Maccallum Cancer Institute
-
Heidelberg West、Victoria、澳大利亚、3081
- Austin and Repatriation Medical Centre
-
-
Western Australia
-
Perth、Western Australia、澳大利亚、6000
- Royal Perth Hospital
-
Perth、Western Australia、澳大利亚、6009
- Sir Charles Gairdner Hospital, Perth
-
-
-
-
-
Istanbul、火鸡、34296
- Vakif Gureba Training Hospital
-
Izmir、火鸡、35220
- Ege University Medical School
-
-
-
-
-
Tallinn、爱沙尼亚、11619
- North-Estonian Regional Hospital Cancer Centre
-
-
-
-
-
Aarau、瑞士、5001
- Kantonspital Aarau
-
Bern、瑞士、CH-3010
- Inselspital, Bern
-
Chur、瑞士、CH-7000
- Ratisches Kantons und Regionalspital
-
Zurich、瑞士、CH-8091
- UniversitaetsSpital
-
-
-
-
-
Birmingham、英国、B29 6JD
- Selly Oak Hospital at University Hospital NHS Trust
-
Oxford、英国、OX3 7LJ
- Churchill Hospital
-
-
England
-
Bristol、England、英国、BS2 8ED
- Bristol Haematology and Oncology Centre
-
Cambridge、England、英国、CB2 2QQ
- Addenbrooke's NHS Trust
-
Cheltenham、England、英国、GL53 7AN
- Cheltenham General Hospital
-
Exeter、England、英国、EX2 5DW
- Royal Devon and Exeter Hospital
-
Guildford、England、英国、GU2 5XX
- Royal Surrey County Hospital
-
Hull、England、英国、HU8 9HE
- Princess Royal Hospital
-
Leeds、England、英国、LS9 7TF
- St. James's Hospital
-
Leicester、England、英国、LE1 5WW
- Leicester Royal Infirmary
-
London、England、英国、SW3 6JJ
- Royal Marsden NHS Trust
-
London、England、英国、NW3 2QG
- Royal Free Hospital
-
London、England、英国、SW17 0QT
- St. George's Hospital
-
London、England、英国、EC1A 7BE
- Saint Bartholomew's Hospital
-
London、England、英国、SE1 9RT
- Guy's and St. Thomas' Hospitals NHS Trust
-
Merseyside、England、英国、CH63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne、England、英国、NE4 6BE
- Newcastle General Hospital
-
Salisbury、England、英国、SP2 8BJ
- Salisbury District Hospital
-
Sheffield、England、英国、S1O 2SJ
- Weston Park Hospital
-
Southampton、England、英国、SO16 6YD
- Southampton General Hospital
-
Sutton、England、英国、SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea、England、英国、SS0 0RY
- Southend NHS Trust Hospital
-
-
Northern Ireland
-
Belfast、Northern Ireland、英国、BT9 7AB
- Belfast City Hospital Trust
-
-
Scotland
-
Dundee、Scotland、英国、DD1 9SY
- Ninewells Hospital and Medical School
-
Glasgow、Scotland、英国、G11 6NT
- Western Infirmary
-
-
Wales
-
Cardiff、Wales、英国、CF4 7XL
- Velindre Cancer Center at Velinde Hospital
-
-
-
-
-
Amsterdam、荷兰、1007 MB
- Vrije Universiteit Medisch Centrum
-
Leiden、荷兰、2300 CA
- Leiden University Medical Center
-
Nijmegen、荷兰、NL-6500 HB
- University Medical Center Nijmegen
-
Rotterdam、荷兰、3075 EA
- Erasmus University Medical Center
-
Utrecht、荷兰、3584 CX
- Academisch Ziekenhuis Utrecht
-
-
-
-
-
Lisbon、葡萄牙、1099-023 Codex
- Instituto Portugues de Oncologia de Francisco Gentil - Centro de Lisboa
-
Porto、葡萄牙、4200
- Instituto Portugues de Oncologia Centro do Porto, SA
-
-
-
-
-
Madrid、西班牙、28041
- Hospital Universitario 12 de Octubre
-
Zaragoza、西班牙、50009
- Hospital Clinico Universitario
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Histologically confirmed previously resected stage III primary cutaneous melanoma or unknown primary with regional lymph node involvement
N1 disease
- Microscopic, nonpalpable nodal involvement
- Primary melanoma of any stage with clinically inapparent N1 regional lymph node metastases (T1-4, N1, M0) detected by elective lymph node dissection or sentinel node biopsy
N2 disease
- Palpable nodal involvement with synchronous primary melanoma or apparent nodal disease after prior excision (any pT, N2, M0)
- Regional lymph node recurrence at any interval after surgery for primary melanoma of any depth (T1-4, rN2, M0)
- Complete resection of primary melanoma with adequate surgical margins
- Full lymphadenectomy must be performed within 70 days of study
- No mucous membrane melanoma or ocular melanoma
- No evidence of distant or nonregional lymph node metastases or in transit metastases (even if previously resected)
- No incompletely resected disease due to gross extracapsular extension
PATIENT CHARACTERISTICS:
Age:
- 18 to 70
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 3,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin at least 9 g/dL
Hepatic:
- SGOT and SGPT less than 2 times upper limit of normal
- No active hepatitis
Renal:
- Creatinine less than 2.0 mg/dL
Cardiovascular:
No severe cardiovascular disease including the following:
- Arrhythmias requiring chronic treatment
- Congestive heart failure (New York Heart Association class III or IV)
- Symptomatic ischemic heart disease
Other:
- No other prior malignancy within the past 5 years except surgically cured nonmelanomatous skin cancer or carcinoma in situ of the cervix
- No thyroid dysfunction unresponsive to therapy
- No uncontrolled diabetes mellitus
- No active autoimmune disease
- No active and/or uncontrolled infection
- No history of neuropsychiatric disorder requiring hospitalization
- No known active alcohol or drug abuse
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior interferon alfa
- No prior immunotherapy for melanoma
- No other concurrent immunologic or biologic therapy
- No concurrent colony stimulating factors including epoetin alfa and filgrastim (G-CSF)
Chemotherapy:
- No prior chemotherapy for melanoma
- No concurrent chemotherapy
Endocrine therapy:
- No prior hormonal therapy for melanoma
- No concurrent hormonal therapy
- No concurrent chronic systemic corticosteroid therapy
Radiotherapy:
- No prior radiotherapy for melanoma
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from any prior recent surgery
Other:
- At least 30 days since other prior experimental therapy
- No other concurrent investigational drugs
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:observation
5 years observation + 5 years follow up
|
|
|
实验性的:pegylated interferon alfa
5 years pegylated interferon alfa + 5 years follow up
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
distant-metastasis free-survival (DMFS)
大体时间:from randomization
|
distant-metastasis free-survival (DMFS) after randomization
|
from randomization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
survival
大体时间:from randomization till death
|
duration of survival: time from randomization until death, whatever the cause
|
from randomization till death
|
|
toxicity
大体时间:from randomization
|
toxicity
|
from randomization
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
quality of life
大体时间:from randomization
|
Quality of life evaluation
|
from randomization
|
合作者和调查者
调查人员
- 学习椅:Alexander M. M. Eggermont, MD, PhD、Daniel Den Hoed Cancer Center at Erasmus Medical Center
出版物和有用的链接
一般刊物
- Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. [Abstract] J Clin Oncol 29 (Suppl 15): A-8506b, 2011.
- Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.
- Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.
- Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009 Jun 20;27(18):2916-23. doi: 10.1200/JCO.2008.20.2069. Epub 2009 May 11. Erratum In: J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.
- Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.
- Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-126. doi: 10.1016/S0140-6736(08)61033-8.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-8504, 473s, 2007.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.